Related Experiment Video
Updated: Mar 7, 2026

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Crizotinib Inhibits Hyperpolarization-activated Cyclic Nucleotide-Gated Channel 4 Activity
Zhushan Zhang1, Tai-Qin Huang1, Igor Nepliouev1
1Department of Medicine, Duke University Medical Center, Durham, NC USA 27710.
Crizotinib, used for lung cancer, can slow heart rate by directly affecting cardiac pacemaker cells. This drug inhibits the HCN4 channel, which is crucial for regulating heart rhythm.
Area of Science:
- Cardiology
- Pharmacology
- Oncology
Background:
- Sinus bradycardia is a common side effect in patients treated with crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor for non-small cell lung cancer (NSCLC).
- Investigated potential direct cardiac effects of crizotinib on heart rate (HR).
Purpose of the Study:
- To determine if crizotinib directly influences heart rate through cardiac mechanisms.
- To elucidate the specific ion channel targets responsible for crizotinib-induced bradycardia.
Main Methods:
- Utilized Langendorff-perfused mouse hearts with ECG analysis to assess crizotinib's effect on HR.
- Employed whole-cell patch clamp technique on mouse sinoatrial node cells (SANCs) and HEK-293 cells expressing human HCN4 to study If currents.
Main Results:
- Crizotinib caused a dose-dependent reduction in HR in isolated mouse hearts (IC50 = 1.7 ± 0.4 μmol/L) without altering cardiac conduction intervals (PR, QRS, QT).
- Crizotinib inhibited the hyperpolarization-activated funny current (If) in SANCs, a key regulator of cardiac pacemaking.
- Diminished HCN4 channel activity (IC50 = 1.4 ± 0.3 μmol/L), slowed activation, and shifted the activation curve of HCN4.
Conclusions:
- Crizotinib's inhibition of HCN4 channels is a primary mechanism underlying its bradycardic effects.
- These findings highlight the direct impact of crizotinib on cardiac electrophysiology.
Related Concept Videos
Inhibition of Cdk Activity
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

